In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $5.61.
According to TipRanks, Bodnar is a 3-star analyst with an average return of 3.3% and a 50.00% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as NovoCure, Celsion, and Olema Pharmaceuticals.
Olema Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $17.40.
Based on Olema Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $23.03 million. In comparison, last year the company had a GAAP net loss of $15.34 million
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OLMA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
Read More on OLMA:
- H.C. Wainwright Keeps Their Buy Rating on Protara Therapeutics (TARA)
- H.C. Wainwright Remains a Hold on Inovio Pharmaceuticals (INO)
- Clearside Biomedical (CLSD) Gets a Buy from H.C. Wainwright
- Assembly Biosciences (ASMB) Gets a Hold from H.C. Wainwright
- AdTheorent Holding (ADTH) Gets a Buy from Needham